Research analysts at William Blair lowered their Q2 2026 earnings estimates for J.Jill in a report released on Thursday, ...
Stock analysts at William Blair issued their FY2026 earnings per share estimates for shares of LENZ Therapeutics in a ...
The Wood County Commission plans to purchase half a dozen ambulances to assist WVU Medicine Camden Clark Medical Center in ...
The Wood County Commission plans to purchase half a dozen ambulances to assist WVU Medicine Camden Clark Medical Center in ...
Fintel reports that on March 21, 2025, William Blair downgraded their outlook for Valmont Industries (NYSE:VMI) from ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
In a report released today, Andy Hsieh from William Blair maintained a Hold rating on BioAge Labs, Inc. (BIOA – Research Report). The company’s ...
As Klarna wins installment lending for the retail giant's OnePay app, rival Affirm seeks to downplay the loss.
We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...
Emerging markets present a landscape of opportunity for equity investors despite macroeconomic headwinds. Click to read.
So while NCAA Tournament teams began preparing for their first-round opponents on Sunday night, Texas won't know who it is ...
Overall, Palantir has had a solid start to 2025. Its growth numbers look impressive, and its AI platform is gaining traction across industries. Yet not everyone is convinced. Some ...